Indazolyl-substituted pyrroline compounds as kinase inhibitors

Details Indazolyl-substituted pyrroline compounds as kinase inhibitors Indazolyl-substituted pyrroline compounds as kinase inhibitors

2007-12-04

2007-12-04

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S254060, C514S306000, C514S338000, C514S307000, C514S406000, C544S371000, C544S140000, C546S325000, C546S143000, C546S159000, C548S361100, C548S362500

Reexamination Certificate

active

10885373

ABSTRACT:
The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I):useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5624949 (1997-04-01), Heath, Jr. et al.
patent: 5721245 (1998-02-01), Davis et al.
patent: 6849643 (2005-02-01), Zhang et al.
patent: 6987110 (2006-01-01), Zhang et al.
patent: 7125878 (2006-10-01), Zhang et al.
patent: 2004/0054180 (2004-03-01), Zhang et al.
patent: 2004/0192718 (2004-09-01), Zhang et al.
patent: 2005/0004201 (2005-01-01), Zhang et al.
patent: 2005/0004202 (2005-01-01), Zhang et al.
patent: 1057484 (2000-12-01), None
patent: 1120414 (2001-08-01), None
patent: WO9517182 (1995-06-01), None
patent: WO9811102 (1998-03-01), None
patent: WO 00/06564 (2000-02-01), None
patent: WO 00/21927 (2000-04-01), None
Xia et al, “Characterization of Vascular Endothelial Growth Factor's Effect on the Activation of Protein Kinase C, Its Isoforms, and Endothelial Cell Growth,” J. Clin. Invest., 1996, pp. 2018-2026, vol. 98, No. 9, The American Society for Clinical Investigation, Inc.
Ishii et al, “Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus,” J. Mol. Med., 1998, pp. 21-31, vol. 76, Dept. of Internal Medicine, Brigham and Women's Hospital: Harvard Medical School, Boston, MA.
Inoguchi et al., “Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation,” Proc. Natl Acad. Sci., 1992, pp. 11059-11063, vol. 89. Medical Sciences.
Bastyr et al, “Increased Platelet Protein Kinase C-β(PKC-β) in IDDM,” DIABETES, 1993, pp. Suppl. 1 97A, 42, Journal of the American Diabetes Association.
Hsieh et al, “Human vitamin D receptor is selectively phosphorylated by proteins kinase C on serine 51, a residue crucial to its trans-activation function,” Pro. Natl. Acad. Sci, 1991, pp. 9315-9319, vol. 8, USA.
Hsieh et al, “Phosphorylation of the Human Vitamin D Receptor by Protein Kinase C,” The Journal of Biological Chemistry, 1993, pp. 15118-15126, vol. 268, USA.
Murray et al, Protein Kinase C Isotypes in Human Erythroleukemia (K562) Cell Proliferation and Differentiation, The Journal of Biological Chemistry, 1993, pp. 15847-15853, vol. 268, No. 21, USA.
Tamaoki et al, “Staurosporine, A potent inhibitor of phospholipids/Ca++Dependent Protein Kinase,” Biochemical and Biophysical Research Communications, 1986, pp. 397-402, vol. 135, No. 2, Academic Press, Inc.
Gross et al, “Characterization of specific [3H]Dimethylstaurosporine Binding to Protein Kinase C.”, Biochemical Pharmacology, 1990, pp. 343-350, vol. 40, Great Britain.
Prudhomme, “Indolocarbazoles as Anti-Cancer Agents,” Current Pharmaceutical Design, 1997, pp. 265-290, vol. 3.
Pindur et al, “Advances in Indolo[2,3-a]carbazole Chemistry: Design and Synthesis of Protein Kinase C and Topoisomerase I Inhibitors,” Current Medicinal Chemistry, 1999, pp. 29-69, vol. 6.
Ruegg et al, “Moledcular pharmacology and drug action: structural information casts light on ligand binding,” Trends in Pharmacological Sciences, 1989, pp. 218-220, vol. 10.
Davis et al, “Potent selective inhibitors of protein kinase C,” FEBS LETT, 1989, pp. 61-63, vol. 259, Elsevier science publishers.
Twomey et al, “The Effect of New Potent Selective Inhibitors of Protein Kinase C on the Neutrophil Respiratory Burst,” Biochemical and Biophysical Research Communications, 1990, pp. 1087-1092, vol. 171, Academic Press, Inc.
Toullec et al, “The Bisindolylmaleimide GF 109203X Is a Potent and Selective Inhibitor of Protein Kinase C,” The Journal of Biological Chemistry, 1991, pp. 15771-15781, vol. 266, USA.
Davis et al, “Inhibitors of Protein Kinase C, 2. Substituted Bisindolylmaleimmides with Improved Potency and Selectivity,” J. Med. Chem. 1992, pp. 994-1001, vol. 35.
Bit et al, “Inhibitors of Protein Kinase C. 3. P tent and Highly Selective Bisindolylmaleimides by Conformati nal Restriction,” J. Med Chem, 1993, pp. 21-29, vol. 36.
McGlynn et al, “Expression and Partial Characterization of Rat Protein Kinase C-σ and Protein Kinase C-ζ in Insect Cells Using Recombinant Baculovirus,” Journal of Cellular Biochemistry, 1992, pp. 239-250, vol. 49.
Ward et al, “Kinetic Analysis of Protein Kinase C Inhibition by Staurosporine: Evidence that Inhibition Entails Inhibitor Binding at a Conserved Region of the Catalytic Domain But Not Competition with Substrates,” Molecular Pharmacology, 1992, pp. 387-392, vol. 41.The American Society for Pharmacology and Experimental Therapeutics.
Martiny-Baron et al, “Selective Inhibition of Protein Kinase C Isozymes by the Indolocarbazole Go 6976,” J. Biol. Chem., 1993, pp. 9194-9197, vol. 268.
Wilkinson et al, “Isoenzyme specificity of bisindolylmleimides, selective inhibitors of protein kinase C,” Biochem J, 1993, 335-337, vol. 294. Great Britain.
Jirousek et al, “(s)-13-[Diomethylamino)methyl]—10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4, 13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase Cβ,” J. Med Chem, 1996, pp. 2664-2671, vol. 39.
Hu, “Recent Discovery and Development of Selective Protein Kinase C Inhibitors”, Drug Discovery Today, 1996, pp. 438-447, vol. 1.
Goekjian et al, “Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development,” Current Medicinal Chemistry, 1999, pp. 877-903, vol. 6, Bentham Science Publishers B.V.
Mulqueen et al, “Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor,” Agents Actions, 1992, pp. 85-89, vol. 37.
Huang et al, “The mechanism of protein kinase C activation,” Trends Neurosci., 1989, pp. 425-432, vol. 12.
Shibata et al, “Neuroprotective effect of protein kinase C inhibitors on oxygen/glucose free-induced decreases in 2-deoxyglucose uptake and CA1 field potentials in rat hippocampal slices,” Brain Res., 1992, pp. 290-294, vol. 594.
Hara et al, “Stauroporine, A Novel Protein Kinase C Inhibitor, PreventsPostischemic Neuronal Damage in the Gerbil and Rat,” Cereb. Blood Flow Metab., 1990, pp. 646-653, vol. 10.Raven Press Ltd., New York.
Shimohama et al, “Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease,” NEUROLOGY, 1993, pp. 1407-1413, vol. 43.
Rotenberg et al, “Protein Kinase C in Neoplastic Cells”, Biochem Mol. Aspects Sel. Cancer, 1991, pp. 25-73, vol. 1.
Ahmad et al, “Expresseion of the Antisense cDNA for Protein Kinase Cα Attenuates Resistance In Doxorubicin-Resistant MCF-Breast Carcinoma Cells,” Molecular Pharmacology, 1993, pp. 858-862, vol. 43.
Meyer et al, “A derivative of Staurosporine (CGP 41 251) shows selectivity for Protein Kinase C Inhibition andIn VitroAnti-Proliferative as Well asIn VivoAnti-Tumor Activity,” Int. J. Cancer, 1989, pp. 851-856, vol. 43.
Akinaga et al, “Antitumor Activity of UCN-01, A Selective Inhibitor of Protein Kinase C, in Murine and Human Tumor Models,” Cancer Research, 1991, pp. 4888-4892, vol. 51.
Matsumoto et al, “Staurosporine, a Protein Kinase C Inhibitor Interferes with Proliferation of Arterial Smooth Muscle Cells,” Biochem and Biophys Research Communications, 1989, pp. 105-109, vol. 158, Academic Press.
Gu et al, “Increased Protein Kinase C and Isozyme Redistribution in Pressure-Overload Cardiac Hypertrop

Affiliated with

Also associated with

Rating

Indazolyl-substituted pyrroline compounds as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indazolyl-substituted pyrroline compounds as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazolyl-substituted pyrroline compounds as kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3897122